GHRH analog family
CJC-1295
The name is used for materially different DAC and non-DAC structures, creating an identity problem.
Why it is discussed
Growth-hormone-axis and body-composition claims
CJC-1295 is discussed for stimulating growth-hormone signaling, often in anti-aging, recovery, or body-composition conversations. The DAC and non-DAC names can refer to materially different structures, and marketed outcomes extend well beyond the limited human pharmacology evidence.
What it is
A growth-hormone-releasing hormone analog with an important naming distinction.
The long-acting CJC-1295 studied in the cited research is a modified growth-hormone-releasing hormone, or GHRH, analog with an albumin-binding component. This component forms a bond with albumin in the blood and prolongs exposure. It is commonly associated with the term DAC, or drug affinity complex.
A product called CJC-1295 without DAC should not automatically be treated as the same molecule. The albumin-binding design and the evidence for the studied long-acting form cannot simply be transferred to that label.
How it works
Stimulating an upstream signal in the growth-hormone pathway.
GHRH-receptor activation signals pituitary cells to release growth hormone. Growth hormone then influences tissues directly and through insulin-like growth factor-1, or IGF-1. CJC-1295 is therefore not growth hormone itself.
A small study in healthy men found increased growth-hormone and IGF-1 measures while pulsatile growth-hormone secretion continued. Pulsatile means release occurs in bursts; it does not mean the overall hormone pattern was unchanged.
Hormone changes are biological measurements, not proof of anti-aging, muscle-building, or recovery benefits. They also do not establish the safety or identity of an unverified product.
Scientific / evidence sources
Evidence at a glance
What is established—and what is not.
Limited human pharmacology plus preclinical evidence
Limited human pharmacology research supports effects on growth-hormone-axis biomarkers for particular studied structures.
Broad recovery, anti-aging, body-composition, combination, and long-term safety claims are not established, and DAC naming ambiguity matters.
Regulatory status
Canada and the United States are checked separately.
No authorized human drug identified in the current source review.
No FDA-approved product; FDA notes limited data and serious adverse-event reports.
Regulatory status describes product authorization and relevant regulatory context. It is not a complete legal opinion about possession, importation, prescribing, sale, or professional practice.
If you are reviewing a product report
The molecule profile and the testing report answer different questions.
This page summarizes evidence and regulatory context. A laboratory report may address identity, purity, or quantity for one submitted sample; it does not transfer clinical evidence or product authorization.